indole-2-sulfonic acid | 74220-55-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: indole-2-sulfonic acid
• 英文别名: Indol-2-sulfonsaeure；Benzazole-2-sulfonic acid；1H-indole-2-sulfonic acid
• CAS: 74220-55-6
• 化学式: C₈H₇NO₃S
• 分子量: 197.214
• InChiKey: MXALRLXMXCYNGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  吲哚 、 pyridine-SO3 complex 生成 indole-2-sulfonic acid
  参考文献：
  名称：

  Terent'ew, Vestnik Moskovskogo Universiteta, 1947, # 6, p. 9,16

  摘要：

  DOI：

文献信息

• [EN] AFFINITY-ASSISTED PROTEIN MODIFICATION AND RECYCLING<br/>[FR] MODIFICATION ET RECYCLAGE DE PROTÉINES BASÉS SUR LEUR AFFINITÉ
  申请人：UNIV CALIFORNIA

  公开号：WO2016118770A1

  公开（公告）日：2016-07-28

  The present invention provides methods for preparing a protein conjugate having a defined number of conjugate groups. The method includes: forming a mixture containing a macrocyclic matrix material and a plurality of proteins; eluting the proteins from the macrocyclic matrix material to obtain a first separated protein fraction and a second separated protein fraction, wherein substantially all of the proteins in the first separated protein fraction have the same number of handle moieties; contacting the handle moieties with a conversion reagent under conditions sufficient to convert the handle moieties in the first separated protein fraction to reactive moieties; and contacting the reactive moieties with a conjugation reagent under conditions sufficient to form a plurality of protein conjugates, wherein substantially all of the protein conjugates in the plurality have the same number of conjugate groups. Also disclosed are methods for recovering enzymes and other proteins from mixtures for isolation and/or reuse of the enzymes and proteins.

  本发明提供了制备具有定义数量结合基团的蛋白共轭物的方法。该方法包括：形成含有大环矩阵材料和多种蛋白质的混合物；从大环矩阵材料中洗脱蛋白质，以获得第一分离的蛋白质分数和第二分离的蛋白质分数，其中第一分离的蛋白质分数中几乎所有蛋白质具有相同数量的手柄基团；将手柄基团与转化试剂接触，在足以将第一分离的蛋白质分数中的手柄基团转化为反应性基团的条件下；将反应性基团与结合试剂接触，在足以形成多种蛋白共轭物的条件下，其中多数蛋白共轭物具有相同数量的结合基团。还公开了从混合物中回收酶和其他蛋白质以便分离和/或重复使用酶和蛋白质的方法。
• NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES
  申请人：Rogers Thomas E.

  公开号：US20130066086A1

  公开（公告）日：2013-03-14

  The present invention provides phosphonate conjugates and methods of preparing the phosphonate conjugates so as to allow, for example, improved methods and compounds for modifying the surface of a nanoparticle to increase in vivo circulation times and targeted delivery performance.

  本发明提供了膦酸酯共轭物及其制备方法，以便例如改进方法和化合物来修改纳米颗粒的表面，从而增加体内循环时间和靶向传递性能。
• BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF
  申请人：BARNES David Weninger

  公开号：US20120028969A1

  公开（公告）日：2012-02-02

  The present invention provides compounds of formula (I); or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (I), their therapeutic uses, combinations with other of pharmacologically active agents, and a pharmaceutical compositions.

  本发明提供了式(I)的化合物；或其药学上可接受的盐，其中变量如本文所定义。本发明提供了一种制造式(I)化合物的方法，它们的治疗用途，与其他药理活性剂的组合，以及药物组成。
• NOVEL SULFONAMIDE DERIVATIVES
  申请人：Banner David

  公开号：US20080167348A1

  公开（公告）日：2008-07-10

  The invention is concerned with the novel sulfonamide derivatives of formula (I) wherein A, R 1 to R 2″ , X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit chymase and can be used as medicaments.

  这项发明涉及公式（I）中的新型磺胺衍生物，其中A、R1到R2″、X和Y的定义如描述和索赔中所述，以及其生理上可接受的盐。这些化合物抑制精氨酶，可用作药物。
• [EN] MITOMYCIN C PRODRUG LIPOSOME FORMULATIONS AND USES THEREOF<br/>[FR] FORMULATIONS DE LIPOSOME DE PROMÉDICAMENT DE MITOMYCINE C ET LEURS UTILISATIONS
  申请人：MALLINCKRODT LLC

  公开号：WO2018089481A1

  公开（公告）日：2018-05-17

  The present invention provides MMC prodrug compounds and liposomal MMC prodrugs and compositions thereof for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid and a MMC prodrug. The present invention also provides liposomal compositions for the treatment of cancer comprising administering to a patient in need thereof a liposome, wherein the liposome comprises: a phosphatidylcholine lipid; a sterol; a PEG-lipid and a MMC prodrug or a pharmaceutically-acceptable salt thereof.

  本发明提供了用于治疗癌症的MMC前药化合物和脂质体MMC前药及其组合物。该组合物包括含有磷脂酰胆碱脂质、固醇、PEG-脂质和MMC前药的脂质体。本发明还提供了用于治疗癌症的脂质体组合物，包括向需要的患者施用脂质体，其中脂质体包括：磷脂酰胆碱脂质；固醇；PEG-脂质和MMC前药或其药用可接受的盐。